SGLT2 Inhibitor, Ipragliflozin, Suglat, Effect on Lipid and Glucose Metabolism Study

Trial Profile

SGLT2 Inhibitor, Ipragliflozin, Suglat, Effect on Lipid and Glucose Metabolism Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Ipragliflozin (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms SUCRE
  • Most Recent Events

    • 26 Jun 2017 Planned End Date changed from 30 Sep 2017 to 30 Sep 2018.
    • 02 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top